Fly News Breaks for December 19, 2019
Dec 19, 2019 | 08:44 EDT
JPMorgan analyst Matthew Holt assumed coverage of Global Blood Therapeutics and keeps an Overweight rating on the name with a price target of $90, up from $80. The analyst believes the Oxbryta launch in sickle cell disease is likely to exceed expectations and that 2020 consensus numbers appear achievable, if not beatable. Further, additional upside in 2020 could come from positive updates on the regulatory pathway in pediatrics in the U.S. and in outside the U.S. geographies, Holt tells investors in a research note.
News For GBT From the Last 2 Days
There are no results for your query GBT